HealthCap

HealthCap, founded in 1996 and headquartered in Stockholm, is a European venture capital firm focused on life sciences. The firm invests globally in companies developing breakthrough therapies that address unmet medical needs, particularly in areas like rare diseases, oncology, and genetic disorders. Over the years, HealthCap has backed more than 127 companies, resulting in over 30 approved pharmaceutical products and 50 medical devices, making it one of the largest specialized life sciences investors in Europe. The firm has raised eight funds to date, with over €1 billion in committed capital. HealthCap's portfolio boasts impressive exits, including companies like OxThera and Aprea Therapeutics, and more than 47 of its portfolio companies have gone public. The firm takes an active role in its investments, with partners frequently joining the boards of portfolio companies, guiding them through clinical trials and regulatory processes. HealthCap’s investment strategy emphasizes precision medicine, targeting innovative therapies that improve patient outcomes. With a strong track record of fostering startups into market leaders, the firm plays a crucial role in shaping the future of healthcare.